MedTrace Logo

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-20

No results posted yet for this study

Summary

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Conditions

Interventions

DRUG

Iptacopan (part 1)

Taken for 52 Weeks

DRUG

Iptacopan (part 2)

Taken for 52 Weeks

DRUG

Placebo + standard of care

Taken for 52 Weeks

DRUG

Iptacopan + placebo

Taken for 52 Weeks

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-10
Primary Completion
2026-03-19
Completion
2028-09-28
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • China
  • Colombia
  • France
  • Germany
  • Hong Kong
  • Hungary
  • India
  • Israel
  • Malaysia
  • Mexico
  • Philippines
  • Portugal
  • Puerto Rico
  • Singapore
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268289 on ClinicalTrials.gov